Jubilant Pharmova Ltd
NSE:JUBLPHARMA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
833.7
1 233
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
JUBLPHARMA Price Targets Summary
Jubilant Pharmova Ltd
According to Wall Street analysts, the average 1-year price target for
JUBLPHARMA
is 1 417.04 INR
with a low forecast of 1 250.38 INR and a high forecast of 1 627.5 INR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is JUBLPHARMA's stock price target?
Price Target
1 417.04
INR
According to Wall Street analysts, the average 1-year price target for
JUBLPHARMA
is 1 417.04 INR
with a low forecast of 1 250.38 INR and a high forecast of 1 627.5 INR.
What is Jubilant Pharmova Ltd's Revenue forecast?
Projected CAGR
13%
For the last 13 years the
compound annual growth rate for
Jubilant Pharmova Ltd's revenue is
4%.
The projected
CAGR
for the next 2 years is
13%.
What is Jubilant Pharmova Ltd's Operating Income forecast?
Projected CAGR
22%
For the last 13 years the
compound annual growth rate for
Jubilant Pharmova Ltd's operating income is
1%.
The projected
CAGR
for the next 2 years is
22%.
What is Jubilant Pharmova Ltd's Net Income forecast?
Projected CAGR
-5%
For the last 13 years the
compound annual growth rate for
Jubilant Pharmova Ltd's net income is
37%.
The projected
CAGR
for the next 2 years is
-5%.
